Please use this identifier to cite or link to this item:
Title: Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes.
Authors: Smith, Samuel G.
Foy, Robbie
McGowan, Jennifer A.
Kobayashi, Lindsay C.
DeCensi, Andrea
Brown, Karen
Side, Lucy
Cuzick, Jack
First Published: 25-May-2017
Publisher: Royal College of General Practitioners
Citation: British Journal of General Practice, 2017, 67 (659), pp. e414-e427
Abstract: BACKGROUND: The cancer strategy for England (2015-2020) recommends GPs prescribe tamoxifen for breast cancer primary prevention among women at increased risk. AIM: To investigate GPs' attitudes towards prescribing tamoxifen. DESIGN AND SETTING: In an online survey, GPs in England, Northern Ireland, and Wales (n = 928) were randomised using a 2 × 2 between-subjects design to read one of four vignettes describing a healthy patient seeking a tamoxifen prescription. METHOD: In the vignette, the hypothetical patient's breast cancer risk (moderate versus high) and the clinician initiating the prescription (GP prescriber versus secondary care clinician [SCC] prescriber) were manipulated in a 1:1:1:1 ratio. Outcomes were willingness to prescribe, comfort discussing harms and benefits, comfort managing the patient, factors affecting the prescribing decision, and awareness of tamoxifen and the National Institute for Health and Care Excellence (NICE) guideline CG164. RESULTS: Half (51.7%) of the GPs knew tamoxifen can reduce breast cancer risk, and one-quarter (24.1%) were aware of NICE guideline CG164. Responders asked to initiate prescribing (GP prescriber) were less willing to prescribe tamoxifen than those continuing a prescription initiated in secondary care (SCC prescriber) (68.9% versus 84.6%, P<0.001). The GP prescribers reported less comfort discussing tamoxifen (53.4% versus 62.5%, P = 0.01). GPs willing to prescribe were more likely to be aware of the NICE guideline (P = 0.039) and to have acknowledged the benefits of tamoxifen (P<0.001), and were less likely to have considered its off-licence status (P<0.001). CONCLUSION: Initiating tamoxifen prescriptions for preventive therapy in secondary care before asking GPs to continue the patient's care may overcome some prescribing barriers.
DOI Link: 10.3399/bjgp17X689377
ISSN: 0960-1643
eISSN: 1478-5242
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © the authors, 2017. This is an open-access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes.pdfPublished (publisher PDF)151.32 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.